Clinical trials: Primary CNS Lymphoma (PCNSL)
Secondary Central Nervous System Lymphoma
R-MTX-zanbrutinib in Secondary CNS Lymphoma
Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor.
- Trial name
- NCT05398224
- Testing
- Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Primary Central Nervous System Lymphoma
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival.
- Trial name
- OptiMATe (NCT04931368)
- Testing
- Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix, Control intervention: four courses of MATRix
- Where
- Germany
- Volunteers
- 331 people
- Sponsor
- Klinikum Stuttgart
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01158274
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
This phase I trial studies the side effects and best dose of pomalidomide when given together with dexamethasone in treating patients with primary central nervous system lymphoma that has come back (relapsed) or does not respond…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
- Trial name
- NCT01722305
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study genetic testing and the effectiveness of irinotecan in treating patients who have solid tumors and lymphoma.
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00003970
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
CNS Lymphoma
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing orelabrutinib on the basis of rituximab and chemotherapy in treating patients with relapsed or refractory B-cell…
- Trial name
- NCT05926427
- Testing
- Orelabrutinib, Rituximab, Chemotherapy
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Lymphoma, Non-Hodgkin, Central Nervous System Neoplasms
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkins Lymphoma (NHL) with rising incidence and variable response to treatment.
- Trial name
- NCT03188354
- Testing
- 18F-FDG, 18F-fluciclovine, standard MRI
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- Norwegian University of Science and Technology
Central Nervous System Tumors
Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）
In this trial, we will treat relapsed PCNSL with temozolomide, pemetrexed. Our objective was to assess our treatment strategies' availability based on response rates, progression-free survival (PFS), median PFS, and toxicity.
- Trial name
- NCT01985451
- Testing
- Pemetrexe, Temozolomide
- Volunteers
- 15 people
- Sponsor
- Rongjie Tao
Primary Central Nervous System Lymphoma
Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of sequential treatment regimens with RO-MTX after pomalidomide, orelabrutinib, rituximab (POR) in…
- Trial name
- NCT05390749
- Testing
- Orelabrutinib, Pomalidomide, Rituximab
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Central Nervous System Lymphoma
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma.
- Trial name
- NCT04548648
- Testing
- Acalabrutinib
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Primary Central Nervous System Lymphoma
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
- Trial name
- NCT02657785
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who…
- Conditions
- EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma, Primary Testicular Lymphoma
- Trial name
- DuRIANS (NCT03212807)
- Testing
- Durvalumab, Lenalidomide
- Where
- 4 sites in Singapore
- Sponsor
- Singapore General Hospital
Primary Central Nervous System Lymphoma
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
This study will evaluate the safety and efficacy of high-dose rituximab combined with temozolomide in the treatment of patients with Primary Central Nervous System Lymphomas (PCNSL).
- Trial name
- NCT02113007
- Testing
- Rituximab plus Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- SCRI Development Innovations, LLC
Primary Non Hodgkin Lymphoma of the Central Nervous System
Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma
The purpose of this study is to determine whether combined chemotherapy [rituximab plus high dosage methotrexate, lomustine, and procarbazine] followed by maintenance therapy with procarbazine is effective in the treatment of…
- Trial name
- PRIMAIN (NCT00989352)
- Testing
- Methotrexate, Lomustine, Procarbazine
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital Freiburg
Lymphoma, B-Cell
The Clinical Implications of Immune Checkpoint Pathways in PCNSL
Central nervous system lymphoma (CNSL) is a rare brain tumor constituting 3% of all newly diagnosed brain tumors, and 2% to 3% of all cases of non-Hodgkin lymphoma. There are two subtypes of CNSL.
- Trial name
- NCT04158128
- Testing
- non-intervention
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- National Taiwan University Hospital
Primary Central Nervous System Lymphoma
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for…
- Trial name
- NCT04737889
- Testing
- Rituximab, Lenalidomide, Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Primary CNS Lymphoma
Diagnosis; Objective RespOnse; THErApy
Thi is a prospective and low-intervention clinical trial. We propose to design a panel of "core" genetic alterations by sequencing Cerebral Spinal Fluid (CSF) DNA in patients with confirmed or suspicious Primary Central Neurvous…
- Trial name
- DOROTHEA (NCT05036564)
- Testing
- Lumbar puncture
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Malignant Tumors, Brain Lymphoma
Usefulness of Gadovist-enhanced FLAIR Imaging
Polyplastic glioblastoma and metastatic brain cancer are the most common malignant brain tumors in adults. The primary diagnostic test for tumors in the brain shows magnetic resonance imaging or similar imaging findings…
- Conditions
- Malignant Tumors, Brain Lymphoma, CNS Lymphoma
- Trial name
- NCT05293990
- Testing
- Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Ryoo, In Seon
Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT03733327
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University